Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
South Africa recently placed
AstraZeneca's (NASDAQ:AZN) COVID-19 vaccine on hold. However, the country began vaccinating some individuals with
Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine, even though it hasn't been authorized or approved yet. In this
Motley Fool Live video
recorded on Feb. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AstraZeneca's pain could be J&J's gain.